Related Experiment Videos

Second-line treatment in invasive mould infections

Meinolf Karthaus1, Oliver A Cornely

  • 1Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Krankenhaus Bielefeld, Med. Klinik Hämatologie/Onkologie und Palliativmedizin im Johannesstift, Bielefeld, Germany. meinolf.karthaus@evkb.de

Mycoses
|September 12, 2006
PubMed

Insights

Invasive fungal infections (IFI) remain a significant threat in cancer patients, with high mortality rates. Recent advancements offer new hope for salvage therapy in refractory cases.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Mycology

Background:

  • Invasive fungal infections (IFI) affect up to 30% of patients with hematological malignancies.
  • IFI, particularly invasive aspergillosis, are associated with high mortality rates exceeding 70%.
  • Current first-line antifungal treatments show response rates of only 40-60%.

Purpose of the Study:

  • To review recent advancements in the diagnosis and treatment of IFI in cancer patients.
  • To highlight novel treatment options for salvage therapy in refractory IFI.
  • To provide an overview of the state-of-the-art management of IFI in this vulnerable population.

Main Methods:

  • Literature review of recent studies on IFI diagnostics and therapeutics.
  • Analysis of new non-culture based diagnostic tools and imaging techniques.
  • Evaluation of emerging antifungal agents and treatment strategies for salvage therapy.

Main Results:

  • Progress in diagnostic tools has improved early detection of IFI.
  • New antifungal agents have shown promise in treating refractory IFI.
  • Salvage therapy options have expanded significantly in the last five years.

Conclusions:

  • Despite advances, IFI remain a critical challenge in cancer care.
  • Novel salvage therapies offer improved outcomes for patients with refractory IFI.
  • Integrated diagnostic and therapeutic strategies are crucial for managing IFI in cancer patients.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: